NATEVBA
(vevasumab)

Natevba® (vevasumab):
Precision targeting in XA+ non-Hodgkin's lymphoma

PI

Exceptional results

Manageable dosing schedule

Natevba® indication

Innovative mode of action

Minimal toxicity

About XA+ NHL

The need for targeted treatment

Summary

Welcome, Dr XXX

What are you most interested in discussing today?

1	2	3	4	5	6

Drag topics to rank

Efficacy	Indication	Mode of action	Safety	Dosing	Disease background

Welcome, Dr XXX

Last time you were most interested in:

Efficacy	Indication	Mode of action	Safety	Dosing	Disease background

What would you like to discuss today?

1	2	3	4	5	6

Drag topics to rank

Efficacy	Indication	Mode of action	Safety	Dosing	Disease background

With Natevba®, precision targeting delivers exceptional results[1]

Over 2 years median PFS[1]

See the data +

Over 80% response rate[1]

See the data +

Meaningful improvements in QoL

See the data +

PFS = progression-free survival; QoL = quality of life.

1. Vincent A et al. *Cancer Therapy and Management* 2020;22(1):87–88.

Natevba® delivers over 2 years median PFS[1]



1. Vincent A et al. *Cancer Therapy and Management* 2020;22(1):87–88.

CI = confidence interval; HR = hazard ratio; PFS = progression-free survival.

Over 80% of patients respond to Natevba®[1]



1. Vincent A et al. *Cancer Therapy and Management* 2020;22(1):87–88.

CI = confidence interval; CR = complete response; ORR = objective response rate.

Natevba® offers clinically meaningful improvements in QoL[1]

Natevba® improved or maintained QoL for the duration of treatment in all five EuroQol domains:

Mobility

Self-care

Usual activities

Pain/ discomfort

Anxiety/ depression

1. Vincent A et al. *Cancer Therapy and Management* 2020;22(1):87–88.

QoL = quality of life.

NATEVBA
(vevasumab)

- Natevba® is an innovative new treatment targeting X-antigen[1]
- Natevba® is indicated for the first-line treatment of X-antigen positive (XA+) non-Hodgkin's lymphoma[1]

1. Natevba® (vevasumab) Summary of Product Characteristics.

Natevba® is the only treatment to target X-antigen, a highly specific marker of malignant lymphocytes[1]

Watch the video below to see Natevba® in action.

1. Natevba® (vevasumab) Summary of Product Characteristics.

Natevba® is the only treatment to target X-antigen, a highly specific marker of malignant lymphocytes[1]



In X-antigen-positive (XA+) non-Hodgkin's lymphoma (NHL), malignant lymphocytes are identifiable by a unique surface marker known as X-antigen.

Natevba® is an antibody-drug conjugate with three parts:

- Antibody specific to X-antigen
- Linker
- Cytotoxic agent

Natevba® recognises X-antigen on malignant lymphocytes and binds strongly. Binding triggers uptake of the drug into the cell. Inside the cell, the linker is cleaved, releasing the cytotoxic agent. This induces apoptotic cell death.

1. Natevba® (vevasumab) Summary of Product Characteristics.

With Natevba®, precision targeting ensures minimal toxicity[1]

Natevba® has a more favourable tolerability profile than chemotherapy, with a lower incidence of Grade 3–4 adverse events[1,2]

Most common adverse events +

Natevba® has a low incidence of haematological adverse events, including neutropenia[1]

Adverse events are generally reversible with appropriate dose adjustments[1]

1. Vincent A et al. *Cancer Therapy and Management* 2020;22(1):87–88.
2. Natevba® (vevasumab) Summary of Product Characteristics.

Most common adverse events observed with Natevba® in phase III clinical development[2]

Frequency	Event
Very common	Infection, diarrhoea, nausea, vomiting, abdominal pain, fatigue, pyrexia.
Common	Dyspnoea, cough, headache, dizziness, weight loss, decreased appetite, alopecia, infusion-related reactions, neutropenia, increased ALT/AST levels.
Uncommon	Thrombocytopenia, leukopenia, anaemia, hyperglycaemia, rash, sepsis.
Rare	Hepatotoxicity, tumour lysis syndrome.
Very rare	Systemic lupus erythematosus.

2. Natevba® (vevasumab) Summary of Product Characteristics.

ALT = alanine aminotransferase; AST = aspartate aminotransferase.

Natevba®'s manageable dosing schedule lets patients get on with life[1]

Natevba® has a convenient 4-weekly infusion schedule[1]

- The recommended dose is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 4 weeks

1

Natevba® is indicated as monotherapy, freeing patients from the burden of chemotherapy[1]

Dose calculator

Patient's body weight (kg)

Recommended dose of Natevba® (mg)

1. Natevba® (vevasumab) Summary of Product Characteristics.

X-antigen positive (XA+) non-Hodgkin's lymphoma (NHL) is a particularly aggressive subtype of NHL, with a poor prognosis[1]

Worldwide, over half a million people are diagnosed with NHL per year[1]



Of these,

15% are XA+[1]

Symptoms of XA+ NHL +

XA+ NHL is an aggressive subtype with rapid progression and a low survival rate[1]



1. Mcguire T et al. *Cancer Therapy Review* 2018;12(4):469–470.

Symptoms are similar to other types of NHL; however, the XA+ subtype progresses quickly, so patients are likely to be diagnosed at a later stage.[1]



1. Mcguire T et al. *Cancer Therapy Review* 2018;12(4):469–470.

NHL = non-Hodgkin's lymphoma; XA+ = X-antigen-positive.

Current treatments do not effectively target malignant cells and therefore have high toxicity[1]

- Unlike in other types of NHL, monoclonal antibody treatments show poor efficacy in XA+ subtypes and are generally not used[1]
- Chemotherapy is the standard of care, but has limited efficacy and high toxicity[1]



1 in 4 XA+ NHL patients discontinue chemotherapy due to adverse events.[1]

NHL = non-Hodgkin's lymphoma; XA+ = X-antigen-positive.

1. Mcguire T et al. *Cancer Therapy Review* 2018;12(4):469–470.

Natevba®:
Precision targeting in XA+ NHL

An innovative new treatment targeting X-antigen[1]

Exceptional results[2]

Minimal toxicity[2]

NHL = non-Hodgkin's lymphoma; XA+ = X-antigen-positive.

1. Natevba® (vevasumab) Summary of Product Characteristics.
2. Vincent A et al. *Cancer Therapy and Management* 2020;22(1):87–88.

We'd love to hear your thoughts on the discussion today

What did you find the most useful part of the discussion today?

Efficacy
Indication
Mode of action
Safety
Dosing
Disease background

What topics would you be interested in receiving further information about?

- [ ] Efficacy
- [ ] Indication
- [ ] Mode of action
- [ ] Safety
- [ ] Dosing
- [x] Disease background

Do you have any other comments about the discussion today?

Save for later

Submit